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The use of substances to enhance human abilities is a constant and cross-cultural feature in the evolution of humanity. Although
much has changed over time, the availability on the Internet, often supported bymisleadingmarketing strategies, hasmade their use
even more likely and risky.This paper will explore the case ofMitragyna speciosa Korth. (kratom), a tropical tree used traditionally
to combat fatigue and improve work productivity among farm populations in Southeast Asia, which has recently become popular
as novel psychoactive substance in Western countries. Specifically, it (i) reviews the state of the art on kratom pharmacology and
identification; (ii) provides a comprehensive overview of kratom use cross-culturally; (iii) explores the subjective experiences of
users; (iv) identifies potential risks and side-effects related to its consumption. Finally, it concludes that the use of kratom is not
negligible, especially for self-medication, and more clinical, pharmacological, and socioanthropological studies as well as a better
international collaboration are needed to tackle this marginally explored phenomenon.
1. Introduction
Kratom (Mitragyna speciosa Korth., of the Rubiaceae family)
is a 4–16-metre high tropical tree, indigenous to Southeast
Asia, the Philippines, and New Guinea. Traditionally, in
certain regions of Southeast Asia, the chopped fresh or dried
leaves of the tree are chewed ormade into tea by local manual
labourers to combat fatigue and improve work productivity
[1]. In addition, kratom preparations have also been used
for centuries during socioreligious ceremonies and to treat
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Figure 1: An estimate of Thai kratom extract composition. The
phytochemicals isolated from various parts of the tree include
overall 40 structurally related alkaloids as well as several flavonoids,
terpenoid saponins, polyphenols, and various glycosides.
various medical conditions, such as morphine dependence
in Thailand [2], and as opium substitute in Malaya [2]. It
has been suggested that the genus was given the “Mitragyna”
name by the Dutch botanist Korthals because the leaves and
the stigmas of the flowers of the plant resemble the shape
of a bishop’s mitre [3]. However, considering its variety of
uses, it could be speculated that the term derives from the
“Mithraic cults,” seen as a source of spiritual transcendence
for thousands of years [4].
Kratom preparations contain varying amounts of several
phytochemicals, making their pharmacological and toxi-
cological evaluation unique and difficult (Figure 1). The
main psychoactive components in the leaves are alkaloids
mitragynine and 7-hydroxymitragynine both found only in
Mitragyna speciosa, but other analogues have been identified
(e.g., speciogynine, paynantheine, and speciociliatine) [3,
4] (Figure 1). The effects of kratom in humans are dose-
dependent where small doses produce stimulatory effects
resembling the stimulant effect of drugs such as cocaine or
amphetamines, while larger dosages tend to be associated
with sedative-narcotic effects that resemble drugs such as
opiates [5].
Imported to Western countries from Southeast Asia,
kratom has become in recent years a popular enhancer,
which could also be classified as novel psychoactive substance
(NPS) [3]. Beyond kratom, some of the most widely used
psychoactive plants, largely not under international control,
include Salvia divinorum, khat (Catha edulis), Hawaiian baby
woodrose seeds (Argyreia nervosa), fly agaric (Amanita mus-
caria), “Magic Mushrooms” (Psilocybe and related species),
Peyote (Lophophora williamsii), Ayahuasca (Banisteriopsis
caapi andPsychotria viridis), and “Genie” (a smokingmixture
containing multiple plant materials and of dubious phar-
macognostical identity) [6]. Natural products often used
as enhancers are exceptionally complex in terms of their
chemistry. This adds complexity of their pharmacological
effects, with a paucity of data relating to the toxicology of
these materials, and even less regarding their interactions
with conventional drugs of abuse [7]. This is further compli-
cated by the possibility of adulteration processes [8].The level
of complexity, variability, and the unknown nature of these
samples, coupled with the risks associated with taking psy-
choactive materials, could offer further risks of ill health by
misadventure, with potentially life-threatening consequences
[9]. In this scenario, predictions of novel psychoactive drug
trends in Western countries specifically suggest that kratom
use will increase in the next years [10].
The aim of the present study was to study this new
phenomenon by (i) reviewing the state of the art on kratom
pharmacology and identification; (ii) providing a compre-
hensive overview of kratom use cross-culturally, ranging
from its traditional use in native societies in Southeast Asia to
its more recent diffusion as a NPS in Western countries; (iii)
exploring the subjective experience of users; (iv) identifying
risks and side-effects related to its consumption.
2. Materials and Methods
A collaborative and multidisciplinary effort to study the
rapid diffusion of kratom was carried internationally by ten
research centres: the School of Life and Medical Sciences,
University of Hertfordshire (United Kingdom), Department
of Neuroscience, Imaging and Clinical Sciences, Gabriele
D’Annunzio University, Chieti (Italy), Centre for Drug
Research, Universiti Sains, Penang (Malaysia), Institute of
Psychology, Eo¨tvo¨s Lora´nd University, Budapest (Hungary),
London School of Economics and Political Science, LSE
Health and Social Care, London (United Kingdom), Depart-
ment of Psychiatry, University of Cambridge, Cambridge
(United Kingdom), Department of Neurology and Psychi-
atry, Sapienza University of Rome, Rome (Italy), School
of Pharmacy and Ph.D. Program in Toxicology, Kaohsiung
Medical University, Kaohsiung (Taiwan), Faculty of Health
Sciences, Semmelweis University, Budapest (Hungary), and
Nyı´ro˝ Gyula Hospital National Institute of Psychiatry and
Addictions, Budapest (Hungary). A review of the literature
(1967–2015) on kratom and its main components was per-
formed in three databases: PsycINFO, PubMed, and Med-
scape. Keywords used to carry out the database searches
included the following: “kratom”, “Mitragyna speciosa”,
“mitragynine”, and “7-hydroxymitragynine”. Peer-review
data that emerged from the search were integrated with
an exploratory qualitative assessment of 227 websites, drug
fora, and other online resources (i.e., e-newsgroups, chat-
rooms, mailing lists, e-newsletters, and bulletin boards).This
was carried out on a regular weekly basis (between January
2008 and April 2015) using the Google search engine in
three languages (English, Italian, and Hungarian). Once the
substance availability of information was identified, further
specific searches were carried out for narratives focusing on
the following issues: (i) motivations behind its recreational
use and possible trends of misuse; (ii) the nature of its
effects on users, including adverse reactions and polydrug
misuse/idiosyncratic combinations; (iii) any other relevant
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information. For the purpose of reporting the results in this
paper, any data collected from online fora, such as usernames
and complete URLs for specific threads that were considered
personal identifiable, were anonymized. Additional searches
were conducted using the Global Public Health Intelligence
Network (GPHIN), a secure Internet-based early warning
system developed by Health Canada and the World Health
Organization (WHO), which monitors media reports in six
languages, Arabic, Chinese, English, French, Russian, and
Spanish.
Permission for the study was granted by the School of
Pharmacy Ethics Committee, University of Hertfordshire,
Hatfield, United Kingdom (November 2013; PHAEC/10-42).
3. Results
113 studies emerged from the literature review and were
critically analysed. Among these, 18 results were considered
not relevant (resulting duplicated, botanical studies, or stud-
ies focusing mainly on other selected chemical compounds)
and therefore excluded. The remaining 95 articles were
further qualitatively analysed and thematically divided in
three main areas of interest related to Mitragyna speciosa
and its main constituents: (1) in vitro and preclinical data
on pharmacology and behavioral effects (𝑁 = 51), (2)
laboratoristic techniques for identification/characterization
(𝑁 = 26), and (3) epidemiological/toxicological reports on
humans (𝑁 = 18). Data on kratom that emerged from the
online searches were identified, monitored, and registered
into 5 categories: (1) epidemiology andmotivation of use; (2)
legal status, methods of purchase, and typical price; (3) forms
of kratom use; (4) subjective pleasurable effects, adverse
effects, and fatal intoxications related to kratom; (5) pattern of
polyabuse. The results from the review of scientific literature
and online sources were comprehensively integrated and
summarized in the following three main subsections: (i)
preclinical data about pharmacology and identification of
kratom constituents; (ii) kratom use in humans in Southeast
Asia; (iii) kratom use in humans in Western countries.
3.1. Pharmacology and Identification of Kratom Constituents.
Kratom has both opioid- and psychostimulant-like subjective
effects [11]. The phytochemicals isolated from various parts
of the kratom tree include over 40 structurally related
alkaloids [7] of which mitragynine (Figure 1) is the most
important with up to 66% purity in the extract of leaves
fromThailand, and only 12% in kratom leaves fromMalaysia.
This alkaloid is the one responsible for analgesic activity
that has been linked to kratom use mostly due to its potent
opioid agonist property [12]. Although mitragynine can act
on the mu (𝜇), kappa (𝜅), and delta (𝛿) opioid receptors, it
is structurally different from morphine and other compo-
nents from the opioid family; the reason why it has been
suggested is that it might also present with a more broad
receptor binding activity [13]. Mitragynine and its analogues
in kratom (including speciogynine (7%), paynantheine (9%),
and speciociliatine (1%) (Figure 1)) are indole alkaloids of the
Corynanthe-type, possessing amonoterpene (iridoid)moiety
[12]. Differently, 7-hydroxymitragynine (Figure 1), a minor
constituent (2%) of M. speciosa, when isolated demonstrates
a potent antinociceptive activity in mice [14]. It is now
considered to be a major contributory factor for the analgesic
properties of M. speciosa due to its selectivity for 𝜇- and
𝜅-opioid receptors [7]. The presence of a hydroxyl group
at C-7 increases the potency of 7-hydroxymitragynine to
be 13- and 46-fold higher than morphine and mitragynine,
respectively, both in vitro and in vivo [12, 15, 16]. This might
be one of the main pharmacological markers of kratom
products’ quality andpotency. Recent studies further revealed
how complex is kratom’s pharmacology, involving a 𝜅-opioid
and dopamine D1 receptors interaction in its various effects
[17]. Serotonergic and adrenergic pathways have also been
involved in the effects of mitragynine, mostly due to its broad
affinity to different receptors [18]. Indeed, the pharmacologi-
calmechanisms responsible for stimulant activity are yet to be
clearly established [19]. Another confounding factormight be
the action of some other isolated compounds (speciociliatine,
speciogynine, and paynantheine), for example, whose effects
were not inhibited by naloxone in animal studies [12, 15].
It is possible that mitragynine is relatively safe at lower
subchronic dose but exhibits toxicity at a highest dose
[20]. However, the erratic pharmacology of kratom makes
it difficult to define a specific dose threshold. According to
online reports and traditional experiences, subjective effects
of kratom depend on the dosage: at low to moderate dose
(1–5 g) it has a mild pleasant stimulant effect; at moderate-
high dose (5–15 g) the compound has opioid-like analgesia
and sedation [20, 21]. No studies have been conducted so
far to determine the blood concentration in patients, and
future approach should consider this point in order to prevent
overdose, considering the possible risk of no response to
naloxone [22, 23]. The standard half-life of mitragynine is
3.85 ± ∼1 hr, depending upon the individuals natural levels
of enzymes and other factors [24, 25]. 7-Hydroxymitragynine
has quite a bit shorter duration, with an average half-life of
2.5 ± 0.7 hours [24, 25]. Recent evidences suggest that the
hydrophobicity, poor water solubility, high variability of drug
release in simulated biological fluids, and acid degradable
characteristics of mitragynine probably further influence the
large variability of its pharmacological responses reported
in the literature [24]. This was confirmed by liver, kidney,
and brain histopathological changes, as well as hematological
and biochemical changes in mice [20]. Mitragynine, 7-
hydroxymitragynine, and mitraphylline exhibit high plasma
protein binding (>90%) determined by equilibrium dialysis
[25]. The metabolism of kratom is mainly hepatic. While
it seems that kratom is unlikely to have any significant
clinical effects on CYP3A4 activity, on the other hand
mitragynine might inhibit other cytochrome P450 enzyme
activities, specifically CYP2D6 [26, 27]. These data indicate
the possibility of a drug interaction if mitragynine and 7-
hydroxymitragynine are coadministered with drugs that are
P-glycoprotein substrates [27].
Current preclinical information on kratom suggests that
this ethnodrug, containing several different active alkaloids,
has a harmful toxicological profile and must be studied in
detail in order to better define its potential as therapeutic
drug [28]. Acute administration of mitragynine produces
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anxiolytic-like effects attributed to the interactions among
opioidergic receptor systems [29]. Other authors attempted
to reveal a possible link with the stress-related corticotropin
pathway [30]. Other evidences show that mitragynine exerts
an antidepressant effect in animal behavioral model inter-
acting with neuroendocrine HPA axis systems [31]. Among
its potential benefits, in addition to analgesic activity [13,
32], mitragynine seems to be also a key component for
the anti-inflammatory properties of kratom by suppressing
prostaglandin E2 (PGE-2) production in the cyclooxygenase
2 (COX-2) pathway [16]. Moreover, some authors claim
that kratom might be promising antioxidant and anticancer
or chemopreventive compounds [33]. Kratom extracts and
mitragynine have been shown to possess cytotoxicity to some
human cancer cell lines, namely, SH-SY5Y cells (neuronal
cells), [34] and avoid the tolerance and dependence on
chronic morphine treatment in mice as well as in human
neuroblastoma SK-N-SHcell [35, 36].Other interesting prop-
erties of the compound might be the capability to modulate
muscle neurogenic contraction [37–39] and gastric secretion
[40].
While kratom metabolites could have the potential to be
developed as new therapeutic agents, there are also possible
serious adverse effects of these materials under investigation.
There have been different studies showing serious conditions
after repeated administration as elevated blood pressure,
nephrotoxic effects [41], impaired cognition and behaviour
[42, 43], dependence potential [42], and hepatic failure [41,
44]. The onset of liver injury is described to occur within
2 to 8 weeks of starting regular use of kratom powder or
tablets, with symptoms of fatigue, nausea, pruritus, and dark
urine followed by jaundice [41, 44].The pattern of liver injury
seems to be typically cholestatic and can be severe with
serum bilirubin levels rising above 20mg/dL [44]. Kratom
constituents were also identified to be potentially cardiotoxic,
ideally potentiating Torsade de Pointes through inhibition
of rapid delayed rectifier potassium current (IKr) in human
cardiomyocytes [45].
At present, kratom constituents are not detected by
conventional drug screening tests: advanced tests like liq-
uid chromatography-tandem or ion-mass spectrometry are
required [7].
3.2. Kratom Use in Southeast Asia
3.2.1. Diffusion and Modalities of Consumption. Mitragyna
speciosa (Rubiaceae) is an indigenous plant of Southeast Asia.
This herbal plant is also known as “kratom,” as “ketum”
or “biak” (Malaysia), or as “krathom” (Thailand, “thom”
in Southern Thailand) and has been used for millennia (a)
as a stimulant; (b) as a remedy in traditional medicine;
and (c) in social context [46, 47]. Historically, manual
labourers (e.g., fisherman, farmers, and rubber-tappers) in
northern Malaysia and southern Thailand commonly used
ketum leaves to improve their work productivity under the
sweltering sun and to relieve fatigue [1]. Rural folk have
traditionally ingested ketum leaves to self-treat common
medical problems (e.g., diabetes, diarrhoea, fever, and pain)
and used it as a wound poultice [46, 48]. Ketumwas also used
as an opium substitute in Malaya during opium scarcity [47].
It is still popularly consumed in Asian communities during
social gatherings in the village [47].
Traditionally, the fresh or dried leaves of kratom are
chewed or brewed into tea or smoked [49]. Ketum is bitter
and sugar or sweet beverages are commonly added to mask
its taste [49]. To experience vigour and euphoria, traditional
“kratom eaters” chew one to three fresh leaves at a time
[1, 2]. Regular and addicted users chew 3–10 times a day [1].
Amattayakul [50] reported that an average green leaf weighs
about 1.7 g and a dry leaf about 0.43 g and twenty kratom
leaves contain about 17mg of mitragynine; no information
is available on other active compounds of the plant. Ketum
is currently widely available in many Asian countries (e.g., in
Malaysia) where it can be easily bought from ketum traders
in the community [1]. Consumers can be classified into two
main groups: the first includes those who solely use ketum to
improve physical tolerance to laborious work and the second
polydrug users who attempt to manage drug withdrawal
symptoms or reduce the intake of other opiates like heroin
[51]. A recent study showed that out-of-treatment opiate users
in Malaysia often use ketum to reduce their dependence
on illicit opiate as well as to ameliorate opiate withdrawal
symptoms [51].
At present, there is no systematic data on the prevalence
of ketum use in all the native countries, but it seems to
be considerable in Malaysia and Thailand. A survey per-
formed in 2007 investigating kratom use in Thailand (26,633
respondents aged 12–65 years) indicated that the lifetime,
past year, and past 30 days prevalences for kratom were
2.32%, 0.81%, and 0.57%, respectively [3]. These figures, with
the exception of lifetime use, were significantly higher than
those for cannabismaking kratom themost widely used illicit
drug in Thailand. Again in Thailand past 30-day prevalence
studies among 13–16-year-old students (𝑛 = 8 708–12 148)
in 2002, 2003, and 2004 showed an increase in the lifetime
use of kratom (from 3.97% to 9.43%) [3]. Another study
in Thailand in 2006 showed a prevalence of psychoactive
drugs in 1,635 motor vehicle drivers: 0.9% were positive to
mitragynine [52]. Overall, reported seizures linked to kratom
quintupled in Thailand from 2005 to 2011, far higher than
those reported for any other drug [6]. Kratom reported
seizures in Malaysia and Myanmar also reached record levels
in 2011, at roughly one ton each [6]. Conversely, in Taiwan,
heroin, methamphetamine, and some new drugs such as syn-
thetic cathinones (methylone, mephedrone, andMDPV) and
synthetic cannabinoids (K2) have been identified since 2000s
according to the Substance Abuse Monitoring and Reporting
Systems (SAMRS), which is a national data collection system
for substance abuse [53]. However, use of kratom and its
major alkaloid mitragynine has not been detected via the
collected information from the SAMRS [53]. Therefore, it
could be suggested that kratom may not yet be a drug of
choice in Taiwan and might still be considered a rather
culture-bounded phenomenon in Asian countries.
The possession of kratom leaves has been illegal in
Thailand since 1943 [49]. Kratom is also controlled in a few
other countries in the region (Malaysia and Myanmar) and
elsewhere (Australia, Bhutan) [6]. In parallel, kratom-related
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arrests more than doubled between 2007 and 2011 in both
Myanmar andThailand [6]. To control its widespread abuse,
ketum was banned in Malaysia and regulated under the
Poisons Act 1952 [49]. Those caught for possessing or pro-
cessing ketum leaves can be fined for approximately RM
2,000 (US 450) or imprisoned if found guilty [49]. The
Malaysian government is in the midst of regulating ketum
under the Dangerous Drugs Act 1952, which will consider the
substances as harmful as opiates and amphetamines [49].
3.2.2. Stigma and Side-Effects. Among rural folk, the believe
that kratom is a better alternative to illicit drugs, such
as heroin and methamphetamine, is still diffuse and it is
mainly used for its invigorating-like effects [54, 55]. Five
to ten minutes after kratom consumption users describe
themselves as feeling happy, strong, and active, especially
among those working in the agricultural sector [1]. They
claim that “their mind is calm” after the consumption of
the drug [1]. Overall, there is no real social stigma towards
ketum users and being dependent on ketum is not seen as
a major problem or taboo in Malaysia, at least for men.
Apparently, society acceptsmale addicts whowork to support
their family but do not accept female addicts [1]. Moreover, it
seems that ketum dependents are not neglecting their family
and the impairment of their social functioning is still under
debate [56]. A recent cross-sectional survey in three northern
states of Peninsular Malaysia investigated 293 regular kratom
consumers [54]. Findings showed that regular kratom users
do not seem to experience major impairments in their
social functioning, despite being dependent on kratom for
prolonged periods [54]. Furthermore, ketum use does not
imply risky behaviours such as needle sharing, common in
heroin dependents [57]. On the other hand, evidence shows
that kratom can generate addiction problems and lead to
other social issues [54]. Considering how kratom use is
consistent, figures for treatment admissions for its use appear
rather low, accounting for, for example, 2 percent of all
drug treatment admissions in Thailand in 2011 (Figure 2).
However, they are declared to be considerably on the rise [6].
Kratom-related treatment admissions almost tripled between
2007 and 2011 (Figure 2) [6]. This could be also partially due
to a more strict antidrug policy, where individuals caught
with kratom are obliged to engage in treatment programs.
Surely, findings show that regular kratom use is associated
with drug dependency, development of withdrawal symp-
toms, and craving [54]. Many regular users declare their
difficulty to abstain from kratom use and experiencing
sharp unpleasant symptoms during abstinence periods [58].
Physical withdrawal symptoms include anorexia, weight loss,
decreased sexual drive, insomnia, muscle spasms and pain,
aching in the muscles and bones, jerky movement of the
limbs, watery eyes/nose, hot flushes, fever, decreased appetite,
and diarrhoea [48, 54]. Psychological withdrawal symptoms
commonly reported are nervousness, restlessness, tension,
anger, hostility, aggression, and sadness [1, 54]. Long-term
addicts are described to become thin and have skin pigmen-
tation on their cheeks, due to the capacity of mitragynine
to increase the production of melanocytes-stimulating sub-
stance [1, 46]. Regular ketum use is also reported to cause
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Figure 2: Kratom-related treatment admissions inThailand almost
tripled between 2007 and 2011. Source: United Nations Office on
Drugs and Crime, Patterns and Trends of Amphetamine-Type
Stimulants and Other Drugs: Asia and the Pacific—2012 (Bangkok,
2012).
psychotic symptoms such as mental confusion, delusion, and
hallucination [1].
Regarding polydrug abuse, in Asia, patterns of com-
plex cointaking involving kratom are also reported. Beyond
“classic” substances and many NPS as synthetic phenylethy-
lamines and cathinones, peculiarly there have been cases
where codeine is added into kratom drinks to obtain a
better “high” or euphoria. In southern Thailand, in recent
years, homemade ice-cold cocktails, called “4 × 100,” have
become popular for their alleged alcohol-mimicking effect
among young Muslim people [3]. The cocktails are made
from kratom leaves, a caffeine-containing soft drink, and
codeine- or diphenhydramine-containing cough syrup as the
three basic ingredients to which ice cubes, an anxiolytic, an
antidepressant, or an analgesic drug is added [3, 59].
So far, there have not been any mortality or toxicity
incidents directly related to ketum use reported in Asian
countries. One possibility is that ketum users in Asia nor-
mally buy fresh ketum juice, from a local known supplier
in the rural area, unlikely to be an adulterated preparation.
Traditionally, ketum in Asia has been used for its stimulant
effects and the dose consumed might be lower than the
one consumed for recreational purposes [19]. But it is also
possible that local health care providers in Asia, perceiving
ketum as a safe traditional herbal drink, might not attribute
some of themedical problems reported by users to ketumuse;
this factor may indeed contribute to the underreporting of
adverse effects among ketum users in Southeast Asia.
3.3. Kratom Use in Western Countries
3.3.1. Diffusion, Modalities, and Reasons of Consumption. In
recent years kratom has become popular in the EU, US,
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and other countries (e.g., Japan) as a recreational novel
compound [3, 6, 60]. A variety ofMitragyna speciosa related
products are easily accessible from local smart shops and
increasingly available for sale on the Internet, in particular on
web based “legal highs” pharmacies, but their exact content is
not always verified [61, 62]. Many different formulations are
available, including raw leaves, capsules, tablets, powder, and
concentrated extracts [49]. Prices vary between countries,
depending on the type and amount of the purchased product,
for example, ranging from 2 to 10 euros per gram for “kratom
15X” extracts, 6 to 15 euros per 10 gram for dried kratom [49],
or sometimes even for lower prices (from less than 1 euro per
gram for “kratom power”) [21, 63–65].
Mitragyna speciosa and/or mitragynine and/or 7-hydrox-
ymitragynine are currently controlled only in a small number
of EU Member States, such as Denmark, Latvia, Lithuania,
Poland, Romania, and Sweden [3]. Kratom is also largely
uncontrolled in the US at a federal level while at the state
level there are some exceptions such as Indiana, Iowa,
Louisiana, and Massachusetts. This means all parts of the
plant and its extracts are legal to cultivate, buy, possess, and
distribute without a license or prescription, and, when sold
as a supplement, sales must conform to US supplement laws
[66]. Recently, in February 2014, the Food and Drug Admin-
istration (FDA) issued “Import Alert 54-15” that seems to
provide customs and border agents broad authority to seize
kratom products from a number of suppliers outside the US
[66].
As kratom is often not monitored in national drug abuse
surveys, there is still little information on prevalence of its
use. An initial warning about this phenomenon has been
launched by the Drug Enforcement Administration (DEA)
as early as 2005 [67]. Internet surveys conducted by the
EMCDDA in 2008 indicated that kratomwas one of the most
widely offered “legal highs” in 44% of the investigated 27
online shops across the EU [3]. A more extensive EMCDDA
Internet survey in July 2011 showed that kratom was the
most widely offered product with 128 out of 631 (or 20%) of
online retailers shipping it to the EU. A further online study
identified 314 online shops selling NPS that would dispatch
products to at least one EU Member State (United Kingdom
appeared to be the most common) [49]. Kratom and Salvia
divinorum were the most frequently offered NPS, available
in 92 and 72 online shops, respectively [3]. In 2012 the term
“kratom” was found in more than two million results. Of the
first 100 websites listed in the search results, 78 were primarily
focused on the sale of kratom, while 22 were focused on
disseminating information about kratom through the use of
discussion boards [5].
3.3.2. Subjective Experience: Online Reports. Since 2001, an
exponential growing number of kratom’s subjective experi-
ences have been posted online by users (Box 1) [64, 68–72].
Kratom can be smoked, but according to users this has no
advantage over chewing ormaking a tea: the amount of leaves
that constitutes a typical dose is too much to be smoked
easily [71, 72]. A paste-like extract can be prepared by lengthy
boiling of fresh or dried leaves and the syrup produced can
be mixed with finely chopped leaves of the palm, made into
pills and smoked in pipes (“madatin”) [26]. Small pellets of
this extract can be ingested, or again the compound can be
dissolved in hot water and consumed alone or mixed with
other ordinary herbal teas to make it more palatable (the so-
called toss andwash) [27, 64, 69]. Other users prefer alcoholic
beverages or to ingest it with food, mixing it with yoghurt or
preparing cookies, in order to contrast the bitterness of the
compound [71, 72]. Regarding desired/recreational effects of
kratom, users report that at low doses it is rather stimulant,
mind is “more alert,” physical energy and sometimes sexual
arousal are increased, and ability to do physical work may
be improved and they also described “entactogenic” effects,
like empathy and euphoria (Box 1) [68, 70, 71]. Some people
find this level edgy rather than pleasant [68, 69]. At higher
doses, experiences describe it as more sedative and analgesic;
users prefer to be less sensitive to physical or emotional
pain, to feel and look calm, and to have a general feeling of
comfortable pleasure [68, 70]. Others report an increase of
empathy feelings (Box 1) [68].
3.3.3. Side-Effects. A variety of less explored side-effects
experienced by users also emerged from our work (Table 1).
These frequently include nausea, constipation, sleep prob-
lems, temporary erectile dysfunction, itching, and sweating
and also hyperpigmentation and tremor and anorexia and
weight loss in long term [64, 68–72]. Some users describe
hair loss, probably related to a regular (daily) use of kratom
[69]. Withdrawal symptoms are also common, including
muscle aches, irritability, mood disturbances, runny nose,
diarrhoea, and muscle jerking (Table 1) [70]. Users describe
tolerance (requiring the consumption of higher doses to
achieve the same effects) and also a “cross-tolerance” to
both kratom and opiates after repeated intake [64, 68–72].
Moreover, kratom is increasingly purchased from Internet
sources for self-medication [3, 61], especially by individuals
with chronic pain to self-manage opioid withdrawal [61, 69]
or heroin, methadone, or suboxone withdrawal symptoms
[68], or for its anxiolytic and antidepressant effects [73].
For this reason, it is often advertised online as a cheaper
alternative to traditional opioid replacement therapies with
no need of medical prescription [28]. This could pose a
serious problem for doctors prescribing pain medication or
opioid substitution therapy to someone who is a regular
kratom user. Adverse effects and intoxications cases across
various countries have also been reported, including liver
toxicity, seizure, and coma [60, 74–76], reports of patients
suffering from intrahepatic cholestasis after two weeks of
kratom use [44], Adult Respiratory Distress Syndrome [77],
and hypothyroidism [78] (Table 1). Evidence also suggests
that kratom might be a deadly substance when mixed with
other compounds (Table 1). Fatalities resulting from the use
of a kratom-based product known as “Krypton” have also
been reported [79] with 9 documented cases in Sweden
[22]. Subsequent forensic studies revealed that Krypton
contained high amounts of the exogenous pharmaceutical
agent O-desmethyltramadol, an opioid analgesic and the
main active metabolite of tramadol, and it had been added
to the plant material. The presence of this contaminant
in some online products is well documented [8, 22, 79].
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“About twenty minutes after ingesting the Kratom, I began to feel a nice, pleasant euphoria
identical to that of an opiate. . .I did notice the simultaneous stimulant/depressant effect like
I notice in hydrocodone or oxycodone”
https://www.erowid.org/experiences/exp.php?ID=53533
“I start to feel this intense warmth come over my entire body, it feels like a combination of
my first MDMA high with a nice OxyContin like twist, along with the social aspect of
Cocaine”
https://www.erowid.org/experiences/exp.php?ID=60574
“I felt my insides become soft and pliable like the onset of most trippy drugs”
https://www.erowid.org/experiences/exp.php?ID=85164
“I felt relaxed, sedated, and free of my normal back and thumb pain in my right hand which
I thought would never be possible. I also felt a nice fuzzy feeling all over which I get from
smoking pot sometimes”
https://www.erowid.org/experiences/exp.php?ID=69677
“I began floating in and out of waking dreams, the ‘nod’, whatever you want to call it, where
you’re not really asleep but you still see dreamlets and dream fragments floating before your eyes.
This goes on for quite some time”.
https://drugs-forum.com/forum/showthread.php?t=9451
“I lost track of time at this point, as I was completely lost in the music and my own thoughts. I
wasn’t really feeling euphoria or a ‘high,’ like when using marijuana. I did feel very ‘stoned’ though,
and I guess I would refer to my state as being high because of my total relaxation and
contentment”.
https://www.erowid.org/experiences/exp.php?ID=93201
“When I’m at the peak, I feel a very pleasant body buzz, kind of like being wrapped around a warm,
soft blanket all day long. On the comedown, I feel relaxed but scatterbrained and my
concentration takes a hit, and I can easily enter ‘waking dreams’ where I’m not sleeping but
dreaming while being unaware of either state of consciousness, which often causes me to jolt
awake and open my eyes”
https://www.erowid.org/experiences/exp.php?ID=101814
Box 1: Qualitative analysis of kratom users’ experiences.
Even though mitragynine was also detected in the products,
it was not determined how the two substances may have
interacted to cause death. Other “deadly cases” are available:
an article described a fatal reaction that appeared to be asso-
ciated with mixing with propylhexedrine (an 𝛼-agonist and
amphetamine-like stimulant, used as decongestant inhalers);
another case indicated that amix of kratom, over-the-counter
cold medications, and benzodiazepines was responsible for
the death of a 17-year-old boy; a postmortem detection of
kratom together with venlafaxine, diphenhydramine, and
mirtazapine was screened in a 24-year man found unrespon-
sive in bed; a middle aged man in therapy with zopiclone,
citalopram, and lamotrigine was found dead at home and
postmortem analysis of peripheral blood revealed high con-
centrations of mitragynine and 7-hydroxymitragynine and
therapeutic values of intake of the other compounds [23, 80,
81].
It must also be noted that kratom is commonly taken
in combination with a variety of other recreational “classic
drugs” (e.g., alcohol, cannabis, benzodiazepines, methadone,
cocaine, amphetamine, and hallucinogenic mushrooms) and
NPS (e.g., kava, mephedrone, and other synthetic cathinones,
tryptamines, and phenylethylamines such as 2C-E, AL-LAD,
and 4-HO-MiPT) [68].
4. Discussion and Conclusions
Indeed, the use of substances to enhance human abilities
is a constant and cross-cultural feature in the evolution of
humanity. Opium, coca leaves, mescaline, and various other
natural substances have been used for millennia in various
cultures for therapeutic purposes, religious ceremonies, and
improvement or modification of the physical and mental
abilities. Although much has changed over time, the drive
for human enhancement has not diminished and drugs
availability on the Internet, often supported by misleading
marketing strategies, has made their use evenmore likely and
risky [9]. In this context,the tropical tree Mitragyna speciosa
Korth. (kratom) has nowplanted its “roots” of use worldwide.
Although the phenomenon has only beenmarginally studied,
an exponential number of kratom’s subjective experiences
have been posted online on drug fora by users in the EU
and US and elsewhere. Kratom, still easily available in native
countries, is now just “a click” away and potentially available
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Table 1: Report of adverse/toxicological effects of kratom.
Short time use effects
Nausea, constipation, sleep problems,
temporary erectile dysfunction,
itching, or sweating
Long time use effects Anorexia, dry mouth, problems indiuresis, darker skin, and hair loss
Withdrawal
symptoms
Hostility, aggression, aching of muscles
and bones, jerky movements of the
limbs, anorexia and weight loss, and
insomnia
Infrequent effects
Seizures (individuals using high doses
of kratom, either alone or combined
with other drugs), intrahepatic
cholestasis, psychotic symptoms, Adult
Respiratory Distress Syndrome, and
hypothyroidism
Fatalities
Kratom mixed with other substances:
O-desmethyltramadol;
propylhexedrine;
over-the-counter cold medications and
benzodiazepines;
venlafaxine, diphenhydramine, and
mirtazapine;
zopiclone, citalopram, and lamotrigine
to wide range of new users, including vulnerable individuals.
As it emerged from our previous studies [9, 82–88], the web
serves also as a repository of information for selected groups,
who can share experiences and suggest new products or
novel modalities of intake via online fora, chat-rooms, blogs,
videos, and others.
Anthropologically, drug addiction history is the complex
history of human vicissitude and desire, as human being is a
desiring being, trying in every way to assuage sufferings, to
enhance feelings of pleasure, and to satisfy inexhaustible and
incessant desires [89]. Even today, the line between socially
acceptable and unlawful use of a variety of psychoactive
products seems to be culture-bound. Kratom is a plant with
a well-established traditional use in South Asia to enhance
work abilities as well as support traditional medicine and
culture, even if officially banned. At the same time, its rapid
diffusion in Western societies, where it is often considered a
“natural” and thus safer option than illicit drugs or an alter-
native to opioid treatment, is not devoid of risks. According
to preclinical data and case reports published in scientific
literature as well as anecdotal experiences posted online,
kratom is not a safe drug. Its consumption is associated
per se with drug dependency, development of withdrawal
symptoms, craving, serious adverse effects, and life-threating
effects, especially in a multidrug-intoxicating scenario [23,
80, 81, 90]. Furthermore, the idea that legality can equate
with the safety of a product might still remain a common
insidious misbelief amongst drug users [91]. On the other
hand, Suwanlert has pointed out in 1975 that “it is hoped
that drug education will be a more effective step towards
kratomuse control” [1], foreseeing the failure of the legislative
measures in South Asian countries.
Kratom pharmacology itself is complex and requires
future research: this compound in fact acts on opioid as well
as on dopaminergic, serotonergic, GABAergic, and adren-
ergic systems [17, 19]. Therefore, subjective effects are very
peculiar ranging from psychostimulant to sedative-narcotic.
Pharmacological mechanisms responsible for several of its
alkaloids activity deserve yet to be clearly established in future
studies. Altogether, available data on kratom suggest caution:
this unregulated plant could exhibit a serious harmful poten-
tial, far beyond any “therapeutic” desired effect; in parallel, its
anxiolytic, antidepressant, and analgesic properties need to be
better explored by scientific research works, like, for example,
in large blind randomized controlled clinical trials [28].
Potential users who tend to self-medicate and health
professionals working with them should be clearly aware of
the risks associated with kratom consumption [92]. As it
emerged from this and other previous studies [93], kratom
is advertised and sold online as “cheaper alternative” to
traditional opioid replacement therapies, as a painkiller for
chronic pain, or as an anxiolytic remedy in psychiatric
population, with no need of medical prescription or supervi-
sion. This encourages a tendency to self-medicate and could
become a serious problem for unaware doctors prescribing
medication to a patient who is a regular kratom user or in
case of acute intoxication related to the substance. Another
issue of concern is the action of other isolated compounds
(e.g., speciociliatine, speciogynine, and paynantheine) whose
effects were not inhibited by naloxone in animal studies [22,
23], meaning a potentially very difficult management in case
of overdose. Therefore, in this scenario, the risk of adverse
reactions or possible misdiagnosis might be very high. It
might also be worth adding that kratom use is not detected
by conventional drug screening tests as advanced tests, like
liquid chromatography-tandem or ion-mass spectrometry,
are required [7]. We also reiterate here the importance of
focusing and asking direct questions on the nature and
patterns of drug intake, includingmedical products diversion
and consumption of NPS, during clinical assessments [94].
Given that nowadays polydrug use represents the norm rather
than the exception, especially in emergency settings [90], the
simultaneous use of drugs should also be promptly iden-
tified, investigated, and well discriminated. Future studies
should explicitly examine the effects of the combination in
complex patterns of polydrug intake, including kratom, to
fully understand the synergistic effects and associated clinical
and toxicological implications. Attention should also be paid
to the motivations behind such behaviours, social norms,
stigma, availability, and other lifestyle factors.
Surely, a possible limitation of our analysis could be
given by the fact that publicly available websites, fora, and
similar sources were also considered and included together
with a systematic literature review. One could wonder about
the limitations of carrying out a risk assessment of a drug
while taking into account also the online comments. It may
be inappropriate to trust information obtained from the
Internet without independent verification and we did not
have any possibility here to ascertain if the substance the
online alleged drug users were taking was indeed kratom. On
the other hand, online reports about kratom seem genuine
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andmany users illustrate their detailed experiences as proper
experiments on themselves.Thus, in the lack of relevant peer-
reviewed data, the online monitoring seems to be indeed a
very useful method to obtain preliminary information about
new and emergent phenomena [95]. Further, as demon-
strated by the outcomes of this study, a better international
collaboration is necessary to tackle this rapidly growing drug
trend.
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